HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Neutrogena

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson has acquired 25,355,205 shares of Neutrogena common stock, approximately 98.6% of the firm's outstanding shares, pursuant to its tender offer that expired Sept. 23, J&J will acquire the remaining shares for $35.25 each, the same price paid in the tender offer, and expects "prompt consummation" of the merger. J&J announced its intention to purchase Neutrogena Aug. 22 for $924.1 mil. ("The Rose Sheet" Aug. 29, p. 1)
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS000910

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel